ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer

Exclusion Criteria

• •Participation in another clinical trial \< 4 weeks prior to enrollment
• •Metastatic disease with one or more of the following:
• •* Liver involvement
• •* Bone pain associated with confirmed evidence of metastases
• •* Non-hepatic visceral involvement
• •The following medications:
• •* Prior treatment with MDV3100, abiraterone, Provenge or TAK700
• •* Prior treatment with ketoconazole
• •* Prior treatment with chemotherapy
• •* Prior radiation therapy completed ≤ 4 weeks prior to enrollment
• •The following medical conditions:
• •* Active angina pectoris
• •* History of Hepatitis B or Hepatitis C
• •* Known HIV infection
• •* Ongoing hypertension